Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (CLARITI)

Immunovia

Status: Completed

Conditions: PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage I; Cancer Diagnosis; Pancreatic Cancer Stage II

Study type: Observational

Funder types: Industry

Identifiers

NCT06947382

CLARITI-10

Details and patient eligibility

About

This is a case-control study to clinically validate the performance of a protein biomarker test to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.

Full description

This case-control study is being conducted to determine the performance of a multiplex protein biomarker model in human serum samples.

Serum samples were collected for analysis from patients with Stages I and II pancreatic ductal adenocarcinoma (PDAC) and non-PDAC controls of similar demographics who were at increased risk of PDAC because their familial or genetic history or clinical symptoms. Investigators and patients will not receive individual patient results, therefore patient care will not be impacted by test results.

Analysis of blood samples will be conducted in Immunovia's laboratory in Durham, NC by personnel who are blinded to subject data. Biomarker results will be analyzed using three predefined (locked) algorithm with predefined (locked) cut-offs resulting in a positive/negative test outcome.

Enrollment: 1,066 patients

Sex: All

Ages: 45+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Informed consent available

• > 45 years of age

• PDAC cases

  • Treatment-naïve, pathologically confirmed PDAC Stage I or Stage II
  • Sporadic or familial/genetic PDAC

• Controls

  • Individuals at high risk for PDAC because of their familial and/or genetic history
  • Individuals with clinical symptoms/signs (e.g. abnormal imaging of the pancreas such as fullness, unexplained weight loss, etc) suggestive of PDAC who were found to NOT have PDAC based on clinical investigation (imaging evidence within 6 months of blood draw)
  • Controls will be selected to have similar demographic features (age/gender) to PDAC patients, as possible.

Exclusion criteria

• Prior treatment for PDAC (i.e., prior resection, radiotherapy, or chemotherapy)

• Current immunosuppressive (e.g. systemic steroid therapy) or chemotherapy

• Major surgery or significant trauma within 12 weeks prior to blood sample collection

• Non-PDAC malignancies within 3 years prior to sample collection squamous or basal cell skin carcinoma is not an exclusion criteria)

• Control patients who currently have

  • biliary obstruction secondary to gallstones
  • prior diagnosis or imaging evidence of chronic pancreatitis
  • cystic pancreatic lesions >3.0 cm in diameter or showing worrisome features according to Fukuoka Consensus Guidelines.

Trial design

1,066 participants in 2 patient groups

PDAC Cases

Description:

Serum samples from patients recently diagnosed with Stage I or Stage II pancreatic adenocarcinoma (PDAC) with no prior treatment for disease

Control

Description:

Serum samples from non-pancreatic adenocarcinoma (PDAC) patients at high-risk for disease due to familial or genetic history or clinical symptoms.